HOB Biotech GroupLtd Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 1/6
HOB Biotech GroupLtd's earnings have been declining at an average annual rate of -14.6%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 12.4% per year. HOB Biotech GroupLtd's return on equity is 4.4%, and it has net margins of 8.8%.
Wichtige Informationen
-14.6%
Wachstumsrate der Gewinne
-21.4%
EPS-Wachstumsrate
| Biotechs Wachstum der Industrie | 11.3% |
| Wachstumsrate der Einnahmen | 12.4% |
| Eigenkapitalrendite | 4.4% |
| Netto-Marge | 8.8% |
| Letzte Ertragsaktualisierung | 30 Sep 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Earnings Not Telling The Story For HOB Biotech Group Corp.,Ltd (SHSE:688656) After Shares Rise 43%
Oct 08
Subdued Growth No Barrier To HOB Biotech Group Corp.,Ltd's (SHSE:688656) Price
Jul 04HOB Biotech GroupLtd's (SHSE:688656) Earnings Are Weaker Than They Seem
May 06Earnings Not Telling The Story For HOB Biotech Group Corp.,Ltd (SHSE:688656) After Shares Rise 25%
Mar 08Aufschlüsselung der Einnahmen und Ausgaben
Wie HOB Biotech GroupLtd Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Sep 24 | 401 | 35 | 160 | 45 |
| 30 Jun 24 | 407 | 46 | 152 | 46 |
| 31 Mar 24 | 399 | 46 | 148 | 47 |
| 31 Dec 23 | 394 | 47 | 141 | 46 |
| 30 Sep 23 | 366 | 36 | 137 | 48 |
| 30 Jun 23 | 360 | 39 | 133 | 45 |
| 31 Mar 23 | 325 | 34 | 126 | 41 |
| 31 Dec 22 | 320 | 42 | 119 | 38 |
| 30 Sep 22 | 336 | 56 | 124 | 36 |
| 30 Jun 22 | 321 | 65 | 112 | 34 |
| 31 Mar 22 | 333 | 86 | 103 | 32 |
| 31 Dec 21 | 318 | 86 | 100 | 31 |
| 30 Sep 21 | 314 | 93 | 91 | 27 |
| 30 Jun 21 | 291 | 83 | 85 | 25 |
| 31 Mar 21 | 262 | 75 | 77 | 24 |
| 31 Dec 20 | 222 | 57 | 70 | 23 |
| 30 Sep 20 | 206 | 48 | 71 | 23 |
| 31 Dec 19 | 259 | 64 | 79 | 24 |
| 31 Dec 18 | 201 | 40 | 60 | 23 |
| 31 Dec 17 | 146 | 21 | 49 | 19 |
| 31 Dec 16 | 112 | 4 | 45 | 22 |
Qualität der Erträge: 688656 has high quality earnings.
Wachsende Gewinnspanne: 688656's current net profit margins (8.8%) are lower than last year (9.8%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 688656's earnings have declined by 14.6% per year over the past 5 years.
Beschleunigtes Wachstum: 688656's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Erträge im Vergleich zur Industrie: 688656 had negative earnings growth (-1.5%) over the past year, making it difficult to compare to the Biotechs industry average (0.08%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 688656's Return on Equity (4.4%) is considered low.